Compare
Veradermics, Inc vs CytomX Therapeutics, Inc. vs Ovid Therapeutics Inc. vs Whitehawk Therapeutics, Inc.
| Latest fiscal year | Veradermics, Inc MANE | CytomX Therapeutics, Inc. CTMX | Ovid Therapeutics Inc. OVID | Whitehawk Therapeutics, Inc. WHWK |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $76.20M | $7.25M | $7.14M |
| Revenue growth (YoY) | n/a | -44.8% | n/m | -72.5% |
| Gross margin | n/a | n/a | n/a | 89.4% (computed) |
| Operating margin | n/a | -29.3% | -585.2% | n/m |
| Net margin | n/a | -22.8% | -240.1% | -288.3% |
| Net income | -$70.00M | -$17.37M | -$17.41M | -$20.60M |
| EPS (Diluted) | -$111.91 | n/a | n/a | -$0.33 |
| Operating cash flow | -$71.60M | -$75.59M | -$38.33M | -$97.43M |
| Free cash flow | -$71.63M | -$75.81M | -$38.33M | -$97.98M |
| Cash & equivalents | $21.77M | $12.67M | $13.15M | $37.57M |
| Total assets | $152.62M | $151.57M | $150.93M | $150.83M |
| Total liabilities | $9.16M | $52.56M | $20.27M | $14.52M |
| Shareholders' equity | -$121.01M | $99.01M | $130.66M | $136.31M |
| Return on year-end equity | n/a | -17.5% | -13.3% | -15.1% |
| Shares outstanding | 749.8K | 170.19M | 130.18M | 47.15M |
Revenue, most recent five fiscal years
| Fiscal year | Veradermics, Inc | CytomX Therapeutics, Inc. | Ovid Therapeutics Inc. | Whitehawk Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | n/a | $76.20M Ended 2025-12-31 | $7.25M Ended 2025-12-31 | $7.14M Ended 2025-12-31 |
| 1 year earlier | n/a | $138.10M Ended 2024-12-31 | $566.0K Ended 2024-12-31 | $25.98M Ended 2024-12-31 |
| 2 years earlier | n/a | $101.21M Ended 2023-12-31 | $392.0K Ended 2023-12-31 | $24.35M Ended 2023-12-31 |
| 3 years earlier | n/a | $53.16M Ended 2022-12-31 | $1.50M Ended 2022-12-31 | $15.22M Ended 2022-12-31 |
| 4 years earlier | n/a | $37.31M Ended 2021-12-31 | $208.38M Ended 2021-12-31 | $14.00M Ended 2021-12-31 |